FDA Maps Pathways To Compliance At Unapproved Drugs Workshop
This article was originally published in The Tan Sheet
Executive Summary
FDA plans to increase enforcement actions against marketed unapproved drugs in the coming year, but hopes to cooperate with firms willing to come to the table seeking approval for currently unapproved products
You may also be interested in...
FDA Sounds Off On Unapproved Ear Drops Through Enforcement Notice
FDA says firms marketing unapproved and misbranded prescription otic products containing one or more of antipyrine, benzocaine, chloroxylenol, hydrocortisone, pramoxine and zinc acetate will be subject to enforcement actions including seizure, injunction and/or criminal proceedings.
FDA Sounds Off On Unapproved Ear Drops Through Enforcement Notice
FDA says firms marketing unapproved and misbranded prescription otic products containing one or more of antipyrine, benzocaine, chloroxylenol, hydrocortisone, pramoxine and zinc acetate will be subject to enforcement actions including seizure, injunction and/or criminal proceedings.
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
Unapproved drugs that "present direct challenges" to FDA's new drug approval and OTC drug monograph systems will be high priority for enforcement actions, according to an agency guidance released June 8